Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis

PHASE2CompletedINTERVENTIONAL
Enrollment

297

Participants

Timeline

Start Date

March 30, 2009

Primary Completion Date

May 4, 2011

Study Completion Date

May 4, 2011

Conditions
Relapsing-remitting Multiple Sclerosis
Interventions
DRUG

BAF312

DRUG

Placebo

Trial Locations (72)

1076

Novartis Investigative Site, Budapest

1145

Novartis Investigative Site, Budapest

3004

Novartis Investigative Site, Drammen

3010

Novartis Investigative Site, Bern

4031

Novartis Investigative Site, Basel

4032

Novartis Investigative Site, Debrecen

5021

Novartis Investigative Site, Bergen

6900

Novartis Investigative Site, Lugano

8091

Novartis Investigative Site, Zurich

10713

Novartis Investigative Site, Berlin

13439

Novartis Investigative Site, Berlin

15213

Novartis Investigative Site, Pittsburgh

20132

Novartis Investigative Site, Milan

20520

Novartis Investigative Site, Turku

25018

Novartis Investigative Site, Montichiari

27607

Novartis Investigative Site, Raleigh

28040

Novartis Investigative Site, Madrid

29607

Novartis Investigative Site, Greenville

32308

Novartis Investigative Site, Tallahassee

33060

Novartis Investigative Site, Pompano Beach

33136

Novartis Investigative Site, Miami

33609

Novartis Investigative Site, Tampa

34093

Novartis Investigative Site, Istanbul

34096

Novartis Investigative Site, Haseki / Istanbul

35058

Novartis Investigative Site, Cullman

35340

Novartis Investigative Site, Izmir

41009

Novartis Investigative Site, Seville

41380

Novartis Investigative Site, Kocaeli

44320

Novartis Investigative Site, Akron

46026

Novartis Investigative Site, Valencia

48013

Novartis Investigative Site, Bilbao

48149

Novartis Investigative Site, Münster

49525

Novartis Investigative Site, Grand Rapids

Novartis Investigative Site, Lengerich

53215

Novartis Investigative Site, Milwaukee

60007

Novartis Investigative Site, Elk Grove Village

60637

Novartis Investigative Site, Chicago

65191

Novartis Investigative Site, Wiesbaden

66100

Novartis Investigative Site, Chieti

79106

Novartis Investigative Site, Freiburg im Breisgau

80112

Novartis Investigative Site, Centennial

81675

Novartis Investigative Site, München

94143

Novartis Investigative Site, San Francisco

98122

Novartis Investigative Site, Seattle

101990

Novartis Investigative Site, Moscow

119049

Novartis Investigative Site, Moscow

121359

Novartis Investigative Site, Moscow

125367

Novartis Investigative Site, Moscow

127018

Novartis Investigative Site, Moscow

129110

Novartis Investigative Site, Moscow

190013

Novartis Investigative Site, Saint Petersburg

197022

Novartis Investigative Site, Saint Petersburg

420103

Novartis Investigative Site, Kazan'

V6T 1Z3

Novartis Investigative Site, Vancouver

K1H 8L6

Novartis Investigative Site, Ottawa

J9J 0A5

Novartis Investigative Site, Gatineau

J4V 2J2

Novartis Investigative Site, Greenfield Park

H3A 2B4

Novartis Investigative Site, Montreal

00930

Novartis Investigative Site, Helsinki

FIN-33520

Novartis Investigative Site, Tampere

01307

Novartis Investigative Site, Dresden

04103

Novartis Investigative Site, Leipzig

H-8200

Novartis Investigative Site, Veszprém

00133

Novartis Investigative Site, Roma

00152

Novartis Investigative Site, Roma

00189

Novartis Investigative Site, Roma

0424

Novartis Investigative Site, Oslo

90-153

Novartis Investigative Site, Lodz

20-954

Novartis Investigative Site, Lublin

02-957

Novartis Investigative Site, Warsaw

08035

Novartis Investigative Site, Barcelona

06100

Novartis Investigative Site, Ankara

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY